The failure of these trials may be attributed to the heterogeneous nature of cancer-associated fibroblasts (CAFs) and the function of fibroblast activation protein (FAP), which can promote tumorigenesis in certain tumours while inhibiting it in others. Here, FAP is linked to neoplasm.